STAMPEDE2 Comparison S - FAQs for Patients

What is Comparison S in STAMPEDE2?

The STAMPEDE2 Comparison S study (also called STAMPEDE2-S) aims to understand whether there is a benefit to adding SABR to standard of care treatment for men whose cancer has spread to only a limited number of areas of the body.

What is oligometastatic prostate cancer?

Oligometastatic prostate cancer is when prostate cancer has only spread to a limited number of areas (up to a total of 5 areas) such as the lymph glands outside of the pelvis and/or the bones. 

In the STAMPEDE2 Comparison S trial, the diagnosis of oligometastatic spread is confirmed by scans done as part of your new or recent diagnosis of prostate cancer.

If you want to know more about oligometastatic prostate cancer, talk to the doctor or nurse who is treating you.

How is oligometastatic prostate cancer usually treated?

Oligometastatic prostate cancer is usually treated with long-term hormonal treatment called androgen deprivation therapy (ADT) given by regular injections, additional oral hormonal therapy and radiotherapy given to the prostate gland.

What are we trying to find out?

If the cancer you currently have is called oligometastatic, this is where the cancer has spread to a limited number of areas in the body (up to a total of 5 areas). We are trying to find out if treating these areas where the cancer has spread with SABR (in addition to having the standard treatment) is a suitable treatment for oligometastatic prostate cancer.

Further information

For more FAQs and answers related to the STAMPEDE2 Comparison S study, please find the Comparison S Patient Information Sheet (PIS) here:

STAMPEDE2 Comparison S PIS V5.0

The Comparison S PIS contains further material on radiotherapy, SABR, screening assessments, possible side effects, and more information on taking part in STAMPEDE2.